|
| Press Releases |
|
 |
|
| Tuesday, December 26, 2017 |
|
|
Nanobiotix: 2017 review and 2018 expected milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. more info >> |
|
|
FDA approves Nanobiotix's first Immuno-Oncology trial |
| A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) more info >> |
|
| Monday, November 13, 2017 |
|
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA. more info >> |
|
| Friday, November 10, 2017 |
|
|
Nanobiotix provides update on the global development of its lead product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3. more info >> |
|
| Monday, October 23, 2017 |
|
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. more info >> |
|
| Friday, September 29, 2017 |
|
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease. more info >> |
|
| Friday, September 1, 2017 |
|
|
Nanobiotix half year results for the six months ended 30 June 2017 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. more info >> |
|
| Friday, June 16, 2017 |
|
|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA. more info >> |
|
| Tuesday, June 6, 2017 |
|
|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
福美達與愛信諾擴大醫療級產品分銷合作
Feb 2, 2026 22:00 HKT/SGT
|
|
|
福美拉与赢创扩大医疗级产品分销合作
Feb 2, 2026 22:00 HKT/SGT
|
|
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 2, 2026 22:00 HKT/SGT
|
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb 2, 2026 21:00: JST
|
|
|
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor
Feb 2, 2026 20:30 HKT/SGT
|
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb 2, 2026 20:00 HKT/SGT
|
|
|
君圣泰医药任命Filip Surmont博士为首席医学官 强化心肾代谢系统疾病（CKM）布局
Feb 2, 2026 18:39 HKT/SGT
|
|
|
卡奧斯遞交招股書：技術築牢根基 盈利穩步增長
Feb 2, 2026 15:46 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 2, 2026 16:29 JST
|
|
|
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 2, 2026 14:30 JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 13:29 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 13:17 HKT/SGT
|
|
|
富士通、ＳＭＢＣ日興証券様のオンライン取引の不正アクセス対策として、生体認証サービスを導入
Feb 2, 2026 12:30: JST
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
